lncRNA MEG3 modified epithelial‐mesenchymal transition of ovarian cancer cells by sponging miR‐219a‐5p and regulating EGFR
Authors:
- 3 June 2019
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (10) , 17709-17722
Abstract
This study was aimed to verify whether there existed any associations between long noncoding RNA MEG3/miR‐219a‐5p/EGFR axis and the development of ovarian cancer (OC). As a whole, we gathered 317 pairs of OC tissues and surgical marginal normal tissues and simultaneously acquired four OC cell lines (ie, A2780, Caov‐3, OVCAR‐3, and SKOV‐3) and human normal ovarian surface epithelial cell line. Moreover, pcDNA3.1‐MEG3, si‐MEG3, miR‐219a‐5p mimic, miR‐219a‐5p inhibitor, pcDNA3.1‐EGFR, and si‐EGFR were, respectively, transfected into the OC cells, and their impacts on viability, proliferation, apoptosis, invasion, and migration of OC cells were assessed via conduction of MTT assay, colony formation assay, flow cytometry assay, transwell assay, and scratch assay. Ultimately, dual‐luciferase reporter gene assay was performed to testify the targeted relationships among maternally expressed gene 3 (MEG3), miR‐219a‐5p, and estimated glomerular filtration rate (EGFR). It was indicated that underexpressed MEG3 and miR‐219a‐5p were significantly associated with unfavorable prognosis of patients with OC when compared with overexpressed MEG3 and miR‐219a‐5p ( P < .05). In addition, the OC cells transfected with si‐MEG3 or miR‐219a‐5p inhibitor exhibited stronger viability, proliferation, invasion, and migration than untreated cells ( P < .05). Correspondingly, the apoptotic percentage of OC cells was reduced observably under treatments of si‐MEG3 and miR‐219a‐5p inhibitor ( P < .05). Moreover, MEG3 exerted modulatory effects on the expression of miR‐219a‐5p ( P < .05), and there was a sponging relationship between them ( P < .05). Finally, EGFR expression was modified by both MEG3 and miR‐219a‐5p significantly ( P < .05), and raising EGFR expression could changeover the impacts of MEG3 and miR‐219a‐5p on the above‐mentioned activity of OC cells ( P < .05). Conclusively, MEG3 could serve as a promising biomarker for diagnosis and treatment of OC, considering its involvement with OC etiology via regulation of miR‐219a‐5p/EGFR axis.Keywords
This publication has 48 references indexed in Scilit:
- Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expressionBMC Cancer, 2013
- miR-219-5p Inhibits Receptor Tyrosine Kinase Pathway by Targeting EGFR in GlioblastomaPLOS ONE, 2013
- Loss of Imprinting and Allelic Switching at the DLK1-MEG3 Locus in Human Hepatocellular CarcinomaPLOS ONE, 2012
- In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of MelanomaCell, 2011
- Isolation and characterization of novel pituitary tumor related genes: A cDNA representational difference approachMolecular and Cellular Endocrinology, 2010
- The IG-DMR and the MEG3-DMR at Human Chromosome 14q32.2: Hierarchical Interaction and Distinct Functional Properties as Imprinting Control CentersPLOS Genetics, 2010
- Increased Expression of Angiogenic Genes in the Brains of Mouse Meg3-Null EmbryosEndocrinology, 2010
- Maternally Expressed Gene 3, an Imprinted Noncoding RNA Gene, Is Associated with Meningioma Pathogenesis and ProgressionCancer Research, 2010
- Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of TongueClinical Cancer Research, 2008
- MicroRNA expression profiles classify human cancersNature, 2005